Ginkgo Bioworks (NYSE: DNA) reported Q4 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $34.76 million versus the consensus estimate of $42.5 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.